May 2, 2012 /
Re-posted News from the MS Foundation
Investigators worldwide are
recruiting 100 people with relapsing-remitting MS for a study testing the use
of a prefilled syringe to administer monthly under the skin injections of the
experimental therapy daclizumab high yield process (DAC HYP). Specifically, the
study is looking at the immune response that is stimulated by this delivery
method, and how the drug is absorbed in the body. This study – also called the
OBSERVE study – is being sponsored by Biogen Idec and Abbott Biotherapeutics.
recruiting 100 people with relapsing-remitting MS for a study testing the use
of a prefilled syringe to administer monthly under the skin injections of the
experimental therapy daclizumab high yield process (DAC HYP). Specifically, the
study is looking at the immune response that is stimulated by this delivery
method, and how the drug is absorbed in the body. This study – also called the
OBSERVE study – is being sponsored by Biogen Idec and Abbott Biotherapeutics.
To learn more about the enrollment criteria for this study, and to find out if
you are eligible to participate, please email neurologyclinicaltrials@biogenidec.com.
..
Comments are appreciated. Note that All comments are moderated
If not yet receiving our weekly e-Newsletter – Click here to: REGISTER –
so that you can be kept up to date with MS News and Information
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
LIKE this BLOG? – Please click the LIKE button top left
so that you can be kept up to date with MS News and Information
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
LIKE this BLOG? – Please click the LIKE button top left
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
